Related Experiment Video

Updated: Mar 22, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

8.0K

Genetic and Functional Sequence Variants of the SIRT3 Gene Promoter in Myocardial Infarction

Xiaoyun Yin1, Shuchao Pang2, Jian Huang2

  • 1Department of Medicine, Shandong University School of Medicine, Jinan, Shandong, China.

Plos One
|April 15, 2016
PubMed

Insights

Genetic variants in the SIRT3 gene promoter may increase myocardial infarction (MI) risk. These variants affect gene activity, potentially contributing to cardiovascular disease development.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Mitochondrial Biology

Background:

  • Coronary artery disease (CAD), including myocardial infarction (MI), is a complex condition often linked to atherosclerosis.
  • While numerous genetic variants are associated with CAD, they explain only a fraction of cases, suggesting a role for rare variants.
  • SIRT3, a mitochondrial deacetylase, is crucial for mitochondrial function and metabolism, and its deficiency is linked to age-related diseases, including cardiovascular issues.

Purpose of the Study:

  • To investigate the role of SIRT3 gene variants in the development of myocardial infarction (MI).
  • To genetically and functionally analyze the SIRT3 gene promoter in MI patients and controls.

Main Methods:

  • Analysis of the SIRT3 gene promoter in a cohort of 319 MI patients and 322 controls.
  • Identification and characterization of DNA sequence variants (DSVs) and single-nucleotide polymorphisms (SNPs).
  • Functional assessment of identified variants' impact on SIRT3 promoter transcriptional activity in HEK-293 and H9c2 cells.

Main Results:

  • Twenty-three DSVs, including 10 SNPs, were identified.
  • Six novel heterozygous DSVs and two SNPs were found exclusively in MI patients.
  • Three SNPs were significantly more frequent in MI patients than controls.
  • Most identified DSVs and SNPs, except one, significantly reduced SIRT3 promoter activity.

Conclusions:

  • The identified DSVs in the SIRT3 gene promoter may contribute to MI development by altering SIRT3 expression levels.
  • These variants represent potential risk factors for MI, highlighting the role of SIRT3 in cardiovascular health.

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K
Murine Myocardial Infarction Model using Permanent Ligation of Left Anterior Descending Coronary Artery08:38

Murine Myocardial Infarction Model using Permanent Ligation of Left Anterior Descending Coronary Artery

Published on: August 16, 2019

29.9K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
652
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
106
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75